Patent · US Active

Therapeutic agents

US8071608B2 · kind B2 · utility

0Cited by

53References

5Claims

0Family size

Assignee

ASTRAZENECA AB · SE

Inventors

Stuart Norman Lile Bennett · Grafton, GB
Rolf Peter Walker · Macclesfield, GB
Michael James Waring · Bebington, GB

Key dates

Filing date	Apr 8, 2010
Grant date	Dec 6, 2011
Priority date	—
Expiry date	Apr 8, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P3/10
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

(2S)-2-[1-(2-Chloro-6-cyano-phenyl)pyrazolo[4,5-e]pyrimidin-4-yl]oxy-3-[(1R)-2-hydroxy-1-methyl-ethoxy]-N-(5-methylpyrazin-2-yl)propanamide or a pharmaceutically acceptable salt thereof is useful in the treatment or prevention of a disease or medical condition mediated through glucokinase (GLK or GK), leading to a decreased glucose threshold for insulin secretion.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.